GE HealthCare launches cloud-based perinatal care solution

CHICAGO - GE HealthCare (NASDAQ:GEHC), a $32.8 billion healthcare technology leader currently trading below its InvestingPro Fair Value, announced Tuesday the launch of CareIntellect for Perinatal, a cloud-based software application designed to help clinicians improve maternal and fetal care by integrating information from multiple clinical sources.

The new solution, which is part of GE HealthCare’s CareIntellect family of applications, combines maternal and fetal vital statistics including uterine activity, blood pressure, fetal heart rate, and maternal SpO2 into a unified view to streamline clinical workflows.

Developed in collaboration with HCA Healthcare, the application incorporates feedback from 29 physicians and 85 nurses across 12 hospitals to ensure its relevance in clinical settings. The solution aims to reduce administrative burden and cognitive overload for healthcare providers.

"That clinical voice informed every stage of development to help ensure relevance and impact at the point of care," said Jeff Caron, Chief Digital and Technology Officer, Patient Care Solutions at GE HealthCare.

Dr. Michael Schlosser, Senior Vice President and Chief Transformation Officer at HCA Healthcare, noted that the collaboration aligns with the organization’s commitment to improving perinatal care and achieving optimal outcomes for mothers and babies.

The CareIntellect platform uses a common cloud infrastructure running on Amazon Web Services, allowing healthcare systems to integrate once and add more applications without requiring product-by-product integration.

GE HealthCare will showcase the new solution at booth #3232 during HLTH 2025, taking place October 19-22 in Las Vegas, Nevada, according to the company’s press release statement. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with additional ProTips and detailed metrics in its Pro Research Report, available for over 1,400 US stocks including GE HealthCare.

In other recent news, GE HealthCare Technologies announced updates to its Intelligent Radiation Therapy software, aiming to significantly reduce the time between cancer diagnosis and treatment. Early adopters of the software have already seen a reduction in simulation to treatment planning time from seven days to just seven minutes. Additionally, GE HealthCare declared a quarterly dividend of $0.035 per share, payable in November to shareholders of record in October. The company also entered an exclusive licensing agreement with Lantheus Holdings to develop and commercialize a prostate cancer diagnostic imaging agent in Japan. Under this agreement, GE HealthCare will handle the development and potential regulatory submissions for the product in Japan.

Meanwhile, GE HealthCare is reportedly exploring strategic options for its China unit, including a possible sale. The company is considering several scenarios, such as selling the entire unit or finding a Chinese partner. In a separate development, shares of GE HealthCare fell after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices. This investigation has introduced new uncertainties for the medical device sector, as noted by Needham.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.